MNG257
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.612
- G2M_CHECKPOINT+0.574
- MYC_TARGETS_V1+0.428
- MITOTIC_SPINDLE+0.404
- MYC_TARGETS_V2+0.383
- ANGIOGENESIS+0.377
- NOTCH_SIGNALING+0.351
- WNT_BETA_CATENIN_SIGNALING+0.289
- UV_RESPONSE_DN+0.287
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.286
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.574
- INTERFERON_GAMMA_RESPONSE-0.456
- INFLAMMATORY_RESPONSE-0.305
- IL6_JAK_STAT3_SIGNALING-0.301
- TNFA_SIGNALING_VIA_NFKB-0.301
- KRAS_SIGNALING_DN-0.260
- MYOGENESIS-0.254
- APOPTOSIS-0.240
- ALLOGRAFT_REJECTION-0.235
- COAGULATION-0.228
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_Z7890YNR | EPN | Supratentorial EPN | 0.891 |
| 2 | MNG409 | — | — | 0.883 |
| 3 | TCGA-22-5483-01A-01R-1820-07 | — | cohortMD1 | 0.873 |
| 4 | DF749F48-6A86-4640-9C62-31B4A7C5D1A9 | — | — | 0.860 |
| 5 | MDT-AP-3334 | Med | Medulloblastoma | 0.860 |
| 6 | MNG1179 | — | — | 0.854 |
| 7 | MNG1000 | — | — | 0.854 |
| 8 | MNG447 | — | — | 0.849 |
| 9 | ERR2598185 | fetal | fetal | 0.848 |
| 10 | MNG753 | — | — | 0.847 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.612 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.574 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.428 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.404 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.383 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.377 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.351 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.289 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.287 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.286 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.276 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.252 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.251 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.249 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.241 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.209 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.193 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.191 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.162 | Inavolisib | — uncovered |
| HYPOXIA | 0.052 | Idelalisib | — uncovered |